Ascentage Pharma (HKG: 6855), based in China, has received approval from the National Medical Products Administration (NMPA) to initiate a multi-center, randomized, double-blind Phase III study evaluating the efficacy of its novel drug, lisaftoclax (APG-2575), in combination with azacitidine (AZA) for the first-line treatment of newly diagnosed patients with higher-risk myelodysplastic syndrome (MDS).
Lisaftoclax is an innovative, orally administered Bcl-2 selective inhibitor designed to treat malignancies by selectively blocking the anti-apoptotic protein Bcl-2, thereby restoring the normal apoptosis process in cancer cells. The drug has shown promising efficacy and tolerability in treating chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and multiple myeloma, among other conditions.- Flcube.com
